Bernard is the new cheerleader for Generex, or NuG
Post# of 36537
i loved his article and the way he compared the two existing technologies that are vying for the cancer treatment paradigms....he does make the case for the li-key, as an important step in the triple negative unmet groups....we will just have to wait for the phase two results coming out from the NSABP and Shenzen??....
I believe that consistent news coming out of these two studies will add value to the NuGenerex share price and value to the company....
As for spin-out of A&E (Nugenerex Immuno Oncology) subsidiary....that is great news for us old timers....and the numbers calculated by TC sound o.k. but could be better, remember this is why we invested in this company in the first place....that and Oralyn......the way i understood TC's number, its about 200 shares for every 1000 we own....so 1 for every five.....i would have liked that number to be 2.5 for every 5....